Relationship between Day 0 dosimetric parameters and biochemical relapse-free survival in patients treated with transperineal permanent prostate interstitial brachytherapy with 125I seeds

被引:2
|
作者
Garran, Cristina [1 ]
Ciervide, Raquel [1 ]
Cambeiro, Mauricio [1 ]
Moreno-Jimenez, Marta [1 ]
Ramos, Luis I. [1 ]
Martinez-Monge, Rafael [1 ]
机构
[1] Univ Navarra, Univ Navarra Clin, Dept Oncol, Div Radiat Oncol, E-31080 Pamplona, Navarre, Spain
关键词
Brachytherapy; Prostate cancer; I-125; Monotherapy; Implant quality; Quantifiers; D-90; V-100 (%); CANCER; RECOMMENDATIONS; RADIOTHERAPY; IMPLANTATION; THERAPY; FAILURE; PD-103; IMPACT; EDEMA;
D O I
10.1016/j.brachy.2009.04.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVES: To determine the relationship between dosimetric parameters obtained on postimplantation Day 0 and biochemical relapse-free survival (bRFS) in patients treated with I-125 transperineal interstitial permanent prostate brachytherapy (TIPPB). METHODS: Two-hundred twenty men with low-risk (n = 155, 70.4%), low-volume intermediate-risk (n = 63, 28.7%), or high-risk (n = 2, 0.9%) prostate cancer were treated with TIPPB between December 2000 and June 2006. Seventy-four (33.6%) patients received short-term (3-6 months) androgen suppression therapy before TIPPB. The median followup for patients free of biochemical failure was of 37.9 months (range, 24.0-84.5 months). RESULTS: The receiver operating characteristic (ROC) analysis established a best-fit cutoff value for the quantifiers D-90 and V-100 of 147 Gy and 92%, respectively. The Kaplan-Meier analysis of bRFS at the cutoff value of D-90 = 147 Gy using the ASTRO, nadir + 2, and combined (ASTRO and nadir + 2) definitions showed a trend toward statistical significance for the ASTRO (p = 0.076) and nadir + 2 (p = 0.064) definitions and a statistically significant correlation for the combined definition (p = 0.033). The corresponding 7-year bRFS for the D-90 > 147 Gy and D-90 <= 147 Gy subsets using the ASTRO, nadir + 2, and combined definitions were 96.5% vs. 89.7% (ASTRO, p = 0.076); 93.7% vs. 70.5% (nadir + 2, p = 0.064); and 94.4 vs. 75.5% (combined, p = 0.033). The V-100 (%) cutoff value of 92% predicted by the ROC analysis was not significant. Among other cutoff values, only D-90 = 140 Gy (p = 0.050) and D-90 = 160 Gy (p = 0.098) showed a trend toward statistical significance when the nadir + 2 and the ASTRO definitions were used. The rest of dosimetric, tumor, and patient parameters did not show statistical correlation with bRFS in the Kaplan-Meier analysis. CONCLUSIONS: The cutoff value of D-90 = 147 Gy obtained on postimplantation Day 0 showed a trend toward significant correlation with bRFS when the standard ASTRO and nadir + 2 definitions were used and a weak but statistically significant correlation with bRFS as per the nonstandard combined definition in a series of patients with predominantly low-risk disease (70.4%) treated at high radiation doses (median D-90 = 152.9 Gy, median V-100 = 92.5%). (C) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 14
页数:7
相关论文
共 27 条
  • [1] Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience
    Nobes, J. P.
    Wells, I. G.
    Khaksar, S. J.
    Money-Kyrle, J. F.
    Laing, R. W.
    Langley, S. E. M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2009, 12 (01) : 61 - 66
  • [2] Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds
    Sugawara, Akitomo
    Nakashima, Jun
    Kunieda, Etsuo
    Nagata, Hirohiko
    Asakura, Hirotaka
    Oya, Mototsugu
    Shigematsu, Naoyuki
    RADIATION ONCOLOGY, 2010, 5
  • [3] LONG-TERM BIOCHEMICAL AND SURVIVAL OUTCOME OF 921 PATIENTS TREATED WITH I-125 PERMANENT PROSTATE BRACHYTHERAPY
    Hinnen, Karel A.
    Battermann, Jan J.
    van Roermund, Joep G. H.
    Moerland, Marinus A.
    Jurgenliemk-Schulz, Ina M.
    Frank, Steven J.
    van Vulpen, Marco
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (05): : 1433 - 1438
  • [4] Kinetics differences between PSA bounce and biochemical failure in patients treated with 125I prostate brachytherapy
    Kanzaki, Hiromitsu
    Kataoka, Masaaki
    Nishikawa, Atsushi
    Uwatsu, Kotaro
    Nagasaki, Kei
    Nishijima, Noriko
    Hashine, Katsuyoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 688 - 694
  • [5] Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds
    Sugawara, Akitomo
    Nakashima, Jun
    Kunieda, Etsuo
    Nagata, Hirohiko
    Mizuno, Ryuichi
    Seki, Satoshi
    Shiraishi, Yutaka
    Kouta, Ryuichi
    Oya, Mototsugu
    Shigematsu, Naoyuki
    RADIATION ONCOLOGY, 2011, 6
  • [6] Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy
    Khaksar, Sara Jane
    Laing, Robert W.
    Henderson, Alastair
    Sooriakumaran, Prasanna
    Lovell, David
    Langley, Stephen E. M.
    BJU INTERNATIONAL, 2006, 98 (06) : 1210 - 1215
  • [7] Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy
    Potters, L
    Cha, C
    Oshinsky, G
    Venkatraman, E
    Zelefsky, M
    Leibel, S
    CANCER JOURNAL, 1999, 5 (05) : 301 - 306
  • [8] Prediction of seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds
    Sugawara, Akitomo
    Nakashima, Jun
    Shigematsu, Naoyuki
    Kunieda, Etsuo
    Kubo, Atsushi
    BRACHYTHERAPY, 2009, 8 (01) : 52 - 56
  • [9] Comparison between preoperative and real-time intraoperative planning 125I permanent prostate brachytherapy: long-term clinical biochemical outcome
    Matzkin, Haim
    Chen, Juza
    German, Larissa
    Mabjeesh, Nicola J.
    RADIATION ONCOLOGY, 2013, 8
  • [10] Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds
    Akitomo Sugawara
    Jun Nakashima
    Etsuo Kunieda
    Hirohiko Nagata
    Ryuichi Mizuno
    Satoshi Seki
    Yutaka Shiraishi
    Ryuichi Kouta
    Mototsugu Oya
    Naoyuki Shigematsu
    Radiation Oncology, 6